Pfizer is recalling two lots of eletriptan hydrobromide (Relpax) 40-mg tablets because of potential contamination withPseudomonasandBurkholderiabacteria, the company has announced. 

The drug is indicated for the acute treatment of migraine with or without aura in adults. 

Patients who consume oral products contaminated with microorganisms are at risk for bacterial dissemination from the gut to the bloodstream, which can result in serious, life-threatening infections, the company cautions. There is also a risk for temporary gastrointestinal distress without serious infection. 

"For the general population, these risks are low; for certain vulnerable patient populations (such as patients with compromised immune systems, cystic fibrosis, and chronic granulomatous disease) there may be the potential for serious adverse events including life-threatening infections," the company noted in a press release. 

To date, Pfizer has not received any customer complaints or reports of adverse events related to this recall. The affected lots were distributed nationwide to wholesalers, retailers, hospitals, and healthcare providers in the United States and Puerto Rico from June 2019 to July 2019.

Table. Specifications for Affected Lots

Carton NDC	Lot #	Exp Date	Strength	Configuration
0049-2340-45	AR5407	Feb 2022	40 mg	Carton w/6 tablets (1 blister card x 6 tablets)
0049-2340-05	CD4565	Feb 2022	40 mg	Carton w/12 tablets (2 blister cards x 6 tablets）

Pfizer has notified its direct customers via a recall letter to arrange for return of any recalled product. Anyone with an existing inventory of the recalled product should stop use and distribution and quarantine immediately.

Healthcare professionals, retailers, and hospitals that have dispensed the product to patients are asked to notify these patients regarding the recall. 

For additional assistance, call Stericycle at 877-225-9750 (Monday through Friday, 8:00 AM to 5:00 PM ET). For medical questions regarding this recall, contact Pfizer Medical Information at 800-438-1985, option 3 (Monday through Friday 9:00 AM to 5:00 PM ET).

 4th China Pharma IP Summit 2019 (CPIPS2019) organized by Shanghai YIP Events, Supported by Pharma IP Right Research Committee of Chinese Pharmaceutical Association, which will be held on 23rd-25th , Oct at Primus Hotel Shanghai Hongqiao China this year. which presents an unrivalled gathering of in-house patent counsel from established and fledgling pharmaceutical and biotechnology companies coming together to listen to updates on patent prosecution and enforceability from global jurisdictions, 
The conference provides delegates with an invaluable opportunity to gain insight into the sector issues of critical current importance; listen to best-in-class case studies; keep abreast of the likely forward impact of key judgements and political jolts; and network with global patent peers.
As a dedicated event to pharmaceutical intellectual property, In the past three years we gathered more than 1000 attendees from relevant government departments, industry associations, global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers and so on. Our topics covered the IP protection in all over the world, include mainly China, Europe, US, Japan, South Korea, India and Emerging Markets. We hope CPIPS could be a good networking and sharing platform for Industry peers, For more information please refer to below and attached agenda or visit conference website: www.pharmaip.cn